论文部分内容阅读
目的观察表达MT1-MMP的乳腺癌细胞株对蒽环类化疗药物敏感性的影响。方法用脂质体Lipofectamine 2000将pcDNA3.1-MT1-MMP真核表达载体转染乳腺癌细胞株MDA-MB-453,然后用含G418的培养基筛选获得过表达MT1-MMP的乳腺癌细胞株。蛋白印迹(Western blotting)技术检测MDA-MB-453细胞内MT1-MMP的表达情况。四唑蓝(MTT)法检测各组细胞对化疗药物的敏感性。结果 Western blotting实验证实,重组载体pcDNA3.1-MT1-MMP真核表达载体成功转入乳腺癌细胞内,并稳定过表达MT1-MMP。MTT法检测发现,阿霉素(ADH)、表阿霉素(EPI)、吡喃阿霉素(THP)转染组细胞的抑制率分别为41.38±1.34%、37.69±1.93%和57.96±3.19%,均明显低于未转染组(70.22±2.55%、70.35±1.21%、76.97±2.70%)和空白质粒组(68.94±1.89%、69.43±1.27%、73.06±1.65%,P<0.05)。结论表达MT1-MMP的乳腺癌细胞株MDA-MB-453对蒽环类化疗药物具有耐药性,MT1-MMP有可能成为一个新的蒽环类化疗药物敏感性预测因子。
Objective To observe the effect of MT1-MMP-expressing breast cancer cell lines on the sensitivity of anthracycline chemotherapy drugs. Methods The eukaryotic expression vector of pcDNA3.1-MT1-MMP was transfected into breast cancer cell line MDA-MB-453 by Lipofectamine 2000. Then the breast cancer cell line over-expressing MT1-MMP was screened by G418-containing medium. . The expression of MT1-MMP in MDA-MB-453 cells was detected by Western blotting. Tetrazolium blue (MTT) method was used to detect the sensitivity of each group of cells to chemotherapy drugs. Results Western blotting experiments confirmed that the recombinant vector pcDNA3.1-MT1-MMP was successfully transfected into breast cancer cells and stably overexpressed MT1-MMP. MTT assay showed that the inhibition rates of adriamycin (ADH), epirubicin (EPI), and pirarubicin (THP) transfected cells were 41.38±1.34%, 37.69±1.93%, and 57.96±3.19, respectively. %, all significantly lower than the non-transfected group (70.22±2.55%, 70.35±1.21%, 76.97±2.70%) and blank plasmid group (68.94±1.89%, 69.43±1.27%, 73.06±1.65%, P<0.05) . Conclusion MT1-MMP-expressing breast cancer cell line MDA-MB-453 is resistant to anthracycline chemotherapy, and MT1-MMP may be a new predictor of sensitivity to anthracycline chemotherapy.